Overview

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Newark Beth Israel Medical Center
Collaborator:
Astellas Pharma Inc
Treatments:
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus